EMA Authorised: Baqsimi (Glucagon) — Amphastar France Pharmaceuticals

View source ↗

Summary

EMA authorised Baqsimi, an intranasal glucagon product, for emergency treatment of severe hypoglycemia in people with diabetes, marketed by Amphastar France Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• BAQSIMI (Glucagon)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Amphastar France Pharmaceuticals. Decision date: 22/08/2025